Genmab Stock - Minor capital increase after employee warrant exercise
18.06.2026 - 16:32:07 | ad-hoc-news.de
Edited by ad hoc news Chart & Technicals Desk. Verified prior to publication on 06/18/2026, 14:30 UTC. Details in the imprint.
Genmab (DK0010272202) has announced a minor capital increase following the exercise of employee warrants. The company reported the issuance of a small number of new shares earlier this week, according to an IR-related press release dated 06/16/2026.
All news and background on Genmab stock
Key corporate updates, regulatory filings and market data on Genmab stock are bundled on our dedicated topic page for interested investors.
Details of the capital increase
According to a press release distributed via newswires, Genmab announced on 06/16/2026 that employees had exercised warrants, triggering the issuance of 185 new ordinary shares with a nominal value of DKK 1 each. The total capital increase is therefore very small in absolute terms.
The new shares were issued as part of Genmab's long-standing warrant incentive programs for employees and management, which are regularly reported through company announcements and, for its Nasdaq listing, via a Form 6-K filing with the US Securities and Exchange Commission.
Thursday focus on chart and technicals
Genmab shares trade on Nasdaq under the ticker GMAB, giving the Danish biotech access to deep US liquidity. As of the latest available quote on Nasdaq, the stock changes hands at around the mid-$20s per share in US dollars, with recent trading reflecting a cautious sentiment toward high-valuation biotech names.
Chart services show that Genmab shares have recently traded below prior 12-month highs and are influenced by broader biotech sector moves on US markets. Against this backdrop, technical indicators such as moving averages and trading volumes help investors gauge whether sentiment is stabilizing or still soft.
How the company makes money
Genmab is a Danish biotech company focused on developing and commercializing antibody-based therapies for cancer and other serious diseases. Its revenue base combines direct product sales, royalties on partnered drugs and milestone payments from large pharmaceutical partners.
Where the stock trades today
Genmab shares (DK0010272202) trade on Nasdaq under the ticker GMAB at $27.45 as of 06/18/2026, 14:30 UTC.
Key facts on Genmab stock
- Company: Genmab A/S
- ISIN: DK0010272202
- WKN: A1C0NH
- Ticker: GMAB
- Venue: Nasdaq
- Price (as of 06/18/2026, 14:30 UTC): 27.45 USD
- Market cap: 18,200,000,000 USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: Standard & Poor's 500 index
- Next earnings date: 08/07/2026
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
